ClinVar Miner

Submissions for variant NM_000535.7(PMS2):c.164-1G>A

gnomAD frequency: 0.00001  dbSNP: rs763308607
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000564457 SCV000670751 likely pathogenic Hereditary cancer-predisposing syndrome 2022-05-10 criteria provided, single submitter clinical testing The c.164-1G>A intronic variant results from a G to A substitution one nucleotide upstream from coding exon 3 of the PMS2 gene. This variant has been identified in cis in the literature and likely in cis in our internal cohort with a pathogenic finding in this same gene in multiple individuals with no reported features of constitutional mismatch repair-deficiency (CMMR-D) but whose Lynch syndrome-associated tumors demonstrated microsatellite instability and/or loss of PMS2 expression by immunohistochemistry (Wang Q et al. J Med Genet, 2020 07;57:487-499; Ambry internal data). This alteration was identified in a cohort of individuals suspected of having a hereditary colon cancer syndrome undergoing multigene panel testing (Baert-Desurmont S et al. Eur. J. Hum. Genet. 2018 11;26:1597-1602). Another study detected this mutation in 0/3030 pancreatic cancer cases and 1/123136 population controls (Hu C et al. JAMA. 2018 06;319:2401-2409). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. Another alteration impacting the same acceptor site (c.164-1G>C) has been detected in multiple probands whose Lynch syndrome-associated tumors demonstrated loss of PMS2 expression by immunohistochemistry (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001280603 SCV001467816 likely pathogenic Hereditary nonpolyposis colon cancer 2020-12-07 criteria provided, single submitter clinical testing Variant summary: PMS2 c.164-1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 3 acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 8.1e-06 in 248116 control chromosomes (gnomAD). c.164-1G>A has been reported in the literature in three individuals affected with Colorectal Cancer and found to be associated in cis with the c.137G>T pathogenic variant (p.Ser46Ile) in these three patients (Wang_2020). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One ClinVar submitter (evaluation after 2014) cites the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Invitae RCV001378577 SCV001576178 likely pathogenic Hereditary nonpolyposis colorectal neoplasms 2023-08-31 criteria provided, single submitter clinical testing This variant is present in population databases (rs763308607, gnomAD 0.0009%). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 484252). This variant has not been reported in the literature in individuals affected with PMS2-related conditions. This sequence change affects an acceptor splice site in intron 2 of the PMS2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816).
Myriad Genetics, Inc. RCV003451261 SCV004187574 likely pathogenic Lynch syndrome 4 2023-09-18 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.
Baylor Genetics RCV003451261 SCV004205472 likely pathogenic Lynch syndrome 4 2023-08-27 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.